innovative drugs in stimulating local blood …...grow and become a global player for rare wound...
TRANSCRIPT
INNOVATIVE DRUGS IN STIMULATING LOCAL BLOOD PERFUSION
TO
ENABLE WOUND HEALING,TREATMENT OF MAJOR EYE AND AGING DISEASES
Reto Naef, PhD, MBACEO and FounderTopadur Pharma AG
Grabenstrasse 11A8952 Schlieren / ZurichSwitzerlandTel. +41 44 755 44 66
© Topadur Pharma AG | January 2020
The Company
Founded2009 GmbH, 2015 AGLocation: Schlieren/ZurichEmployees: 17 (12 FTEs)
FINANCIALS (past)15.5 M US$ equity3.5 M US$ non-dilutive1.6 M US$ pending
CURRENT EQUITY ROUND8-12 M US$ Expected exit: 2022
NEXT MILESTONESFIH (TOP-N53)
Problem Indications & MarketsChronic non-healing wounds, excessive scar formationOcular blood flow, medical cosmetics
PDE5enzyme
inhibitioncGMP
sGCenzyme
stimulation
Topadur Drug Platform
Topadur invented LMW drugs based on two key enzymes incGMP metabolism, leading to increased blood perfusion,
stimulating angiogenesis and tissue regeneration to enable new therapies for several indications with high medical needs.
Local application of the angiogenetic drug candidates is expected to result in sustainable disease modification.
Invention & Solution
© Topadur Pharma AG | January 2020
ManagementLeadership and Board Members
150 years in total - within Pharma
LEADERSHIP TEAM BOARD MEMBERS
Dr. Guido Koch
COO
Dr. Reto Naef
CEO & President of Board
Dr. Hermann Tenor
CSO
Christina Attaalla
CFODr. Christian Ludin
Head Development,
Legal & Secretary o. B.
Pascal Brenneisen
Investor, Legal, Marketing
Prof. Dr. Günther Wess
R&D, Diabetes
Dr. Dominik Escher
Serial Founder,
Ophthalmology
© Topadur Pharma AG | January 2020
Endothelial Dysfunction -The Solution
Topadur’s unique Drug Platform - based on sGC Stimulation and PED5 Inhibition
© Topadur Pharma AG | January 2020
Key target cells
Cellular targets and funcional effects increasing cGMP signaling; Topadur’s dual MoA drugs
Cell type Functional effect of cGMP
stimulation
Vascular smooth muscle Blood perfusion
Endothelial cells Angiogenesis
Retinal ganglion cells Neuroprotection
Hair cells Preservation
Fibroblasts Anti-fibrotic
Intestinal epithelial cells Prevention of colorectal tumors
Head and neck SCC Growth retardation. aptoptosis
© Topadur Pharma AG | January 2020
Wound healingAngiogenesis
TOP-N53 1st priority
• Diabetic foot ulcers• Orphan ulcera• Decubitus• Major surgery
Scar preventionAnti-fibrotic
TOP-N443rd priority
• Burn wounds• Skin fibrosis• Fibrotic lung/eye
diseases
Opportunistic R&D
TOP-M119TOP-N53; TOP-V122
• Pulmonary ArterialHypertension
• Medical CosmeticsAlopecia, Skin aging
• HNSCC & colon cancerCancer stem cells
Ocular blood flowNeuroprotection
TOP-V1222nd priority
• Glaucoma• dry AMD• Diabetic
Retinopathy
Portfolio andPrioritiesR & D Portfolio
© Topadur Pharma AG | January 2020
lead finding profiling in vitro POC in vivo POC toxicology FIH Phase 1 Phase 2a/b Phase 3
preclinical clinical
Priority Projects
Opportunistic Projects
Pipeline Overview
DFU & wound healing
Scar formation, burn wounds
Normal tension glaucoma
PAH, hair growth, skin aging, Chemotherapy induced hair loss
Colorectal cancer prevention,Elimination cancer stem cells
Projects forearly Partnering
Drug Candidate - Development
© Topadur Pharma AG | January 2020
Company development strategy
Maximize value
generation
Focus on Topadur priority projects
Grow and become a global player for rare wound healing indications
2019 2021 2023 2025Exit
2022
Maximize value from Topadur’s unique
IP platform through early partnering and
out-licensing after preclinical in vivo proof of concept
Bring Topadur’s priority projects to
clinical proove of concept before out-licensing
to global partners
Become a global
player in a niche
Market after IPO
© Topadur Pharma AG | January 2020
TOP-N53: Wound Healing
TOP-M119: Alopecia
TOP-V122: Ophthalmic indications
0
1000
2000
3000
4000
5000
6000
7000
2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040
Total future Sales & Profits - 3 Main Drug Products
future sales TOP-N53+TOP-M119+TOP-V122+TOP-T5
future profits main products TOP-N53+TOP-M119+TOP-V122+TOP-T5
Mio USD
Expected longer-term Future Sales & Profits -Outlook for Valuation
Expected Sales & Profits - 3 most advanced Drug Products
© Topadur Pharma AG | January 2020
OverviewFinancials
Financial Forecast
© Topadur Pharma AG | January 2020
1. TOP-N53 2. TOP-V122, TOP-T5DIABETES FOOT GLAUCOMA, OPHTHAPAH PAH (back-up)
3. TOP-M119 4. TOP-N44ALOPECIA BURN WOUNDSHEARING LOSS
“HEALTH IS THE MOST IMPORTANT THING“
- Winner - IMD Startup 2016
- Top 100 - Swiss Startups 2017
- Winner - Swiss Innovation Challenge 2017
- Winner - Venture Leaders China 2018
- Winner - SEF High-Tech Award 2018
- Top 100 - Swiss Startups 2018
- Winners - Pitching Battle CEO day 2015
- Finalist - Swiss Innovation Challenge 2015
- Winner - Venture Leaders Life Science 2016
- Top 100 - Swiss Startups 2016
- CTI - Label Company 2016
- Top 100 - Swiss Startups 2019
- IPIEC Global Top 10 (2100 start-ups) 2019
- Winner 2019 WIPO
AWARDS: